Skip to main content

Dana-Farber Research Publication 9.1.2022

Welcome to Dana-Farber's Research News

View Archive Newsletters

September 1, 2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors. If you are a Dana-Farber faculty member and you think your paper is missing from Research News, please let us know at:

Annals of Oncology

Deciphering Radiological Stable Disease to Immune Checkpoint Inhibitors

Luo J

BACKGROUND: 'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset of patients with SD who are benefiting from treatment. Understanding SD would facilitate drug development and improve precision in correlative research.
PATIENTS AND METHODS: A systematic review was carried out to characterize SD in ICI trials. SD and objective response were compared to proliferation index using The Cancer Genome Atlas gene expression data. To identify a subgroup of SD with outcomes mirroring responders, we examined a discovery cohort of non-small-cell lung cancer (NSCLC). Serial cutpoints of two variables, % best overall response and progression-free survival (PFS), were tested to define a subgroup of patients with SD with similar survival as responders. Results were then tested in external validation cohorts.
RESULTS: Among trials of ICIs (59 studies, 14 280 patients), SD ranged from 16% to 42% in different tumor types and was associated with disease-specific proliferation index (ρ = -0.75, P = 0.03), a proxy of tumor kinetics, rather than relative response to ICIs. In a discovery cohort of NSCLC [1220 patients, 313 (26%) with SD to ICIs], PFS ranged widely in SD (0.2-49 months, median 4.9 months). The subset with PFS >6 months and no tumor growth mirrored partial response (PR) minor (overall survival hazard ratio 1.0) and was proposed as the definition of SD responder. This definition was confirmed in two validation cohorts from trials of NSCLC treated with durvalumab and found to apply in tumor types treated with immunotherapy in which depth and duration of benefit were correlated.
CONCLUSIONS: RECIST-defined SD to immunotherapy is common, heterogeneous, and may largely reflect tumor growth rate rather than ICI response. In patients with NSCLC and SD to ICIs, PFS >6 months and no tumor growth may be considered 'SD responders'. This definition may improve the efficiency of and insight derivable from clinical and translational research.


Tissue-Resident Memory and Circulating T Cells are Early Responders to Pre-Surgical Cancer Immunotherapy

Luoma AM, Suo S, Gunasti L, Porter CBM, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, Uppaluri R, Haddad RI, Ashenberg O, Regev A, Van Allen EM, Schoenfeld JD, Wucherpfennig KW

Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer patients treated with neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4 in a clinical trial (NCT02919683). Tumor-infiltrating CD8 T cells that clonally expanded during immunotherapy expressed elevated tissue-resident memory and cytotoxicity programs, which were already active prior to therapy, supporting the capacity for rapid response. Systematic target discovery revealed that treatment-expanded tumor T cell clones in responding patients recognized several self-antigens, including the cancer-specific antigen MAGEA1. Treatment also induced a systemic immune response characterized by expansion of activated T cells enriched for tumor-infiltrating T cell clonotypes, including both pre-existing and emergent clonotypes undetectable prior to therapy. The frequency of activated blood CD8 T cells, notably pre-treatment PD-1-positive KLRG1-negative T cells, was strongly associated with intra-tumoral pathological response. These results demonstrate how neoadjuvant checkpoint blockade induces local and systemic tumor immunity.

Journal of Clinical Oncology

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Lipsyc-Sharf M, Santos K, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Winer EP, Lin NU, Parsons HA

PURPOSE: To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor-positive breast cancer (HR+ BC) more than 5 years from diagnosis.
METHODS: We enrolled 103 patients with high-risk stage II-III HR+ BC diagnosed more than 5 years prior without clinical evidence of recurrence. We performed whole-exome sequencing (WES) on primary tumor tissue to identify somatic mutations tracked via a personalized, tumor-informed ctDNA test to detect minimal residual disease (MRD). We collected plasma at the time of consent and at routine visits every 6-12 months. Patients were followed for clinical recurrence.
RESULTS: In total, 85 of 103 patients had sufficient tumor tissue; of them, 83 of 85 (97.6%) patients had successful whole-exome sequencing. Personalized ctDNA assays were designed targeting a median of 36 variants to test 219 plasma samples. The median time from diagnosis to first sample was 8.4 years. The median follow-up was 10.4 years from diagnosis and 2.0 years from first sample. The median number of plasma samples per patient was two. Eight patients (10%) had positive MRD testing at any time point. Six patients (7.2%) developed distant metastatic recurrence, all of whom were MRD-positive before overt clinical recurrence, with median ctDNA lead time of 12.4 months. MRD was not identified in one patient (1.2%) with local recurrence. Two of eight MRD-positive patients had not had clinical recurrence at last follow-up.
CONCLUSION: In this prospective study, in patients with high-risk HR+ BC in the late adjuvant setting, ctDNA was identified a median of 1 year before all cases of distant metastasis. Future studies will determine if ctDNA-guided intervention in patients with HR+ BC can alter clinical outcomes.

Journal of Clinical Oncology

Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment

Yurgelun MB, Uno H, Furniss CS, Ukaegbu C, Horiguchi M, Chittenden A, Garber JE, Syngal S

PURPOSE: With the availability of multigene panel testing (MGPT) for hereditary cancer risk assessment, clinicians need to assess the likelihood of pathogenic germline variants (PGVs) across numerous genes in parallel. This study's aim was to develop and validate a clinical prediction model (PREMMplus) for MGPT risk assessment.
MATERIALS AND METHODS: PREMMplus was developed in a single-institution cohort of 7,280 individuals who had undergone MGPT. Logistic regression models with Least Absolute Shrinkage and Selection Operator regularization were used to examine candidate predictors (age, sex, ethnicity, and personal/family history of 18 cancers/neoplasms) to estimate one's likelihood of carrying PGVs in 19 genes (broadly categorized by phenotypic overlap and/or relative penetrance: 11 category A [APC, BRCA1/2, CDH1, EPCAM, MLH1, MSH2, MSH6, biallelic MUTYH, PMS2, and TP53] and eight category B genes [ATM, BRIP1, CDKN2A, CHEK2, PALB2, PTEN, RAD51C, and RAD51D]). Model performance was validated in nonoverlapping data sets of 8,691 and 14,849 individuals with prior MGPT ascertained from clinic- and laboratory-based settings, respectively.
RESULTS: PREMMplus (score 2.5%) had 93.9%, 91.7%, and 89.3% sensitivity and 98.3%, 97.5%, and 97.8% negative-predictive value (NPV) for identifying category A gene PGV carriers in the development and validation cohorts, respectively. PREMMplus assessment (score 2.5%) had 89.9%, 85.6%, and 84.2% sensitivity and 95.0%, 93.5%, and 93.5% NPV, respectively, for identifying category A/B gene PGV carriers. Decision curve analyses support MGPT for individuals predicted to have 2.5% probability of a PGV.
CONCLUSION: PREMMplus accurately identifies individuals with PGVs in a diverse spectrum of cancer susceptibility genes with high sensitivity/NPV. Individuals with PREMMplus scores 2.5% should be considered for MGPT.

Journal of Clinical Oncology

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline

Ligibel JA, Meyerhardt JA

PURPOSE: To provide guidance on exercise, diet, and weight management during active cancer treatment in adults.
METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials evaluating the impact of aerobic and resistance exercise, specific diets and foods, and intentional weight loss and avoidance of weight gain in adults during cancer treatment, on quality of life, treatment toxicity, and cancer control. PubMed and the Cochrane Library were searched from January 2000 to May 2021. ASCO convened an Expert Panel to review the evidence and formulate recommendations.
RESULTS: The evidence base consisted of 52 systematic reviews (42 for exercise, nine for diet, and one for weight management), and an additional 23 randomized controlled trials. The most commonly studied types of cancer were breast, prostate, lung, and colorectal. Exercise during cancer treatment led to improvements in cardiorespiratory fitness, strength, fatigue, and other patient-reported outcomes. Preoperative exercise in patients with lung cancer led to a reduction in postoperative length of hospital stay and complications. Neutropenic diets did not decrease risk of infection during cancer treatment.
RECOMMENDATIONS: Oncology providers should recommend regular aerobic and resistance exercise during active treatment with curative intent and may recommend preoperative exercise for patients undergoing surgery for lung cancer. Neutropenic diets are not recommended to prevent infection in patients with cancer during active treatment. Evidence for other dietary and weight loss interventions during cancer treatment was very limited. The guideline discusses special considerations, such as exercise in individuals with advanced cancer, and highlights the critical need for more research in this area, particularly regarding diet and weight loss interventions during cancer treatment. Additional information is available at

Journal of Clinical Oncology

Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?

Amonoo HL, El-Jawahri A, Deary EC, Traeger LN, Cutler CS, Antin JA, Huffman JC

Positive psychological health is crucial to optimal clinical outcomes across the cancer care continuum, from prevention and risk reduction to palliative care and survivorship. Yet, the positive psychological factors that affect morbidity and mortality have not been extensively studied in diverse oncologic populations compared with other medical populations—although they could be extremely influential in a cancer population facing a life-threatening diagnosis. Positive psychological well-being (PPWB), a broad construct defined as “the positive cognitions, feelings, and strategies individuals use to evaluate their life favorably and function well,” includes indicators such as positive affect, gratitude, optimism, happiness, and life purpose. Although PPWB coexists with symptoms of distress, it is not simply the opposite of distress. For example, optimism and depression are only modestly inversely correlated. Many studies in medical populations have found that the beneficial effects of positive psychological health on clinical outcomes are independent of the adverse effects of negative psychological conditions like depression on clinical outcomes. Hence, the primary focus of alleviating symptoms of distress and psychiatric disorders to achieve optimal psychological health in oncology populations ignores an essential aspect of well-being: overcoming adversity and accentuating life-affirming perspectives that may enhance the positive aspects of well-being. Importantly, supporting PPWB should not be confused with the tyranny of positive thinking (ie, where patients feel pressured to think positively and may believe that failure to think positively is a character flaw that can lead to poor clinical outcomes and disease setbacks).

Journal of the National Cancer Institute

Variation in Cardiac Dose Explains a "Fraction" of the Disparities among Breast Cancer Patients

Punglia RS, Hassett MJ

Most studies on disparities in cancer have focused on differences in stage of diagnosis and access to treatment. Breast cancer death rates are highest among vulnerable populations, including African Americans, the poor, the elderly, and those living in rural settings. Few prior studies have look at differences in the characteristics of administered treatments as a potential explanation for observed disparities in outcomes. In medical oncology, an analysis of chemotherapy administered to breast cancer patients found African-Americans received 10% lower relative dose intensity compared to white patients. In this issue of the Journal, Dr. Chapman and colleagues present a novel and intricate analysis of the mediators of racial disparities among women receiving whole breast radiation therapy, using mean heart dose as the vehicle for their examination.

Lancet Oncology

PI3K Inhibitors in Haematological Malignancies

Brown JR, LaCasce AS, Davids MS

We are writing in response to the Comment by Nicholas Richardson and colleagues from the US Food and Drug Administration, which discussed the use of PI3K inhibitors in haematological malignancies. As investigators who have treated many patients with PI3K inhibitors, beginning with the phase 1 study of idelalisib in 2010, we can attest to the transformative and life-saving nature of these therapies. Many of the patients whom we have treated with PI3K inhibitors have derived great benefit for 5 years or more while on therapy. The Comment by Richardson and colleagues does not address well established approaches to patient selection, toxicity management, or the clinical benefit of PI3K inhibitors. Two of the three original idelalisib randomised registration trials in patients with relapsed chronic lymphocytic leukaemia showed both progression-free survival and overall survival benefits in patients who received idelalisib rather than placebo in combination; this was confirmed in long-term follow-up. A study published in 2021 showed improved overall response rates, progression-free survival, and overall survival in different subgroups of patients who developed autoimmune toxicity on idelalisib. PI3K inhibitors remain an important option for older patients who might not be candidates for BTK inhibitors due to cardiovascular comorbidities or anticoagulation. Comorbidities did not negatively affect outcomes in patients treated with PI3K inhibitors. The complexities of venetoclax dose ramp-up have also led to low uptake, except in academic centres. These considerations underscore the need to consider all PI3K inhibitor trials in different clinical settings and the limitations of other therapies.

Nature Cell Biology

Nucleotide Imbalance Decouples Cell Growth from Cell Proliferation

Nabel CS, Darnell Do BT, Vander Heiden MG

Nucleotide metabolism supports RNA synthesis and DNA replication to enable cell growth and division. Nucleotide depletion can inhibit cell growth and proliferation, but how cells sense and respond to changes in the relative levels of individual nucleotides is unclear. Moreover, the nucleotide requirement for biomass production changes over the course of the cell cycle, and how cells coordinate differential nucleotide demands with cell cycle progression is not well understood. Here we find that excess levels of individual nucleotides can inhibit proliferation by disrupting the relative levels of nucleotide bases needed for DNA replication and impeding DNA replication. The resulting purine and pyrimidine imbalances are not sensed by canonical growth regulatory pathways like mTORC1, Akt and AMPK signalling cascades, causing excessive cell growth despite inhibited proliferation. Instead, cells rely on replication stress signalling to survive during, and recover from, nucleotide imbalance during S phase. We find that ATR-dependent replication stress signalling is activated during unperturbed S phases and promotes nucleotide availability to support DNA replication. Together, these data reveal that imbalanced nucleotide levels are not detected until S phase, rendering cells reliant on replication stress signalling to cope with this metabolic problem and disrupting the coordination of cell growth and division.

Nature Cell Biology

Untangling the Web of Intratumour Heterogeneity

Li Z, Seehawer M, Polyak K

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and disease progression. Technological and computational advances have enabled us to assess ITH at unprecedented depths, yet this accumulating knowledge has not had a substantial clinical impact. This is in part due to a limited understanding of the functional relevance of ITH and the inadequacy of preclinical experimental models to reproduce it. Here, we discuss progress made in these areas and illuminate future directions.

Nature Medicine

Predicting Chronic Morbidity in Childhood Cancer Survivors

Vrooman LM, Diller LR

Approximately 85% of children diagnosed with cancer will be cured of their primary cancer, but epidemiologic and clinical studies have characterized a significant burden of morbidity, as well as excess early mortality, in survivors. This burden has largely been attributed to toxic treatment exposures during childhood cancer treatment. Excess cardiovascular-related disease is a leading cause of morbidity and mortality in survivors of childhood cancer, which is associated with exposure to cardiotoxic therapy, such as anthracyclines and therapeutic radiation to the chest. Traditional cardiometabolic risk factors, including obesity, also contribute to an increased risk of cardiovascular disease in survivors as they age, and survivors of childhood cancers have been found to have high rates of obesity.


Mitochondrial Remodeling and Ischemic Protection by G Protein-Coupled Receptor 35 Agonists

Wyant GA, Yu W, Doulamis IP, Nomoto RS, Saeed MY, Duignan T, McCully JD, Kaelin WG Jr

Kynurenic acid (KynA) is tissue protective in cardiac, cerebral, renal, and retinal ischemia models, but the mechanism is unknown. KynA can bind to multiple receptors, including the aryl hydrocarbon receptor, the a7 nicotinic acetylcholine receptor (a7nAChR), multiple ionotropic glutamate receptors, and the orphan G protein-coupled receptor GPR35. Here, we show that GPR35 activation was necessary and sufficient for ischemic protection by KynA. When bound by KynA, GPR35 activated Gi- and G12/13-coupled signaling and trafficked to the outer mitochondria membrane, where it bound, apparantly indirectly, to ATP synthase inhibitory factor subunit 1 (ATPIF1). Activated GPR35, in an ATPIF1-dependent and pertussis toxin-sensitive manner, induced ATP synthase dimerization, which prevented ATP loss upon ischemia. These findings provide a rationale for the development of specific GPR35 agonists for the treatment of ischemic diseases.

American Journal of Medicine

Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials

Riaz IB, Sonpavde GP, Kehl KL, Duma N 

Annals of Hematology

Anti-CD38 Antibody Therapy for Patients with Relapsed/Refractory Multiple Myeloma: Differential Mechanisms of Action and Recent clinical Trial Outcomes

Richardson PG

Annals of Surgical Oncology

Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ

Tesch ME, Collins LC, Wong JS, Dominici L, Tamimi R, Come SE, Partridge AH

Annals of Surgical Oncology

Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy

Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA

Blood Advances

Organ-Specific Response After Low-Dose Interleukin-2 Therapy for Steroid-Refractory Chronic Graft-Versus-Host Disease

Kim HT, Koreth J, Whangbo J, Nikiforow S, Reynolds CG, Stowe P, Ho VT, Cutler C, Antin JH, Soiffer RJ, Ritz J

BMJ Open

Cancer Treatment Decision-Making Among Parents of Paediatric Oncology Patients in Guatemala: A Mixed-Methods Study

Mack JW

Bone Marrow Transplantation

Peer Support in Patients with Hematologic Malignancies: A Systematic Review

Amonoo HL, Harnedy LE, Staton SC, Daskalakis E, El-Jawahri A, Huffman JC

Bone Marrow Transplantation

Peer Support in Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Qualitative Study

Amonoo HL, Harnedy LE, Deary EC, Traeger L, Daskalakis EP, Cutler C, Kelkar AH, Rosales R, Goldschen L, Pirl WF, Feig EH, Revette A, Huffman JC, El-Jawahri A

British Journal of Haematology

Orthopaedic Adverse Events Among Adolescents and Adults Treated with Asparaginase for Acute Lymphoblastic Leukaemia

Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR

Breast Cancer Research and Treatment

Outcomes After Treatment of Breast Cancer During Pregnancy Including Taxanes and/or Granulocyte Colony-Stimulating Factor Use: Findings from a Multi-Institutional Retrospective Analysis

Sella T, Ren S, Freret TS, Economy KE, Chen WY, Parsons HA, Lin NU, Moy B, Tung NM, Partridge AH, Tayob N, Mayer EL

Breast Cancer Research and Treatment

The Prevalence and Predictors of Adjuvant Chemotherapy Use Among Patients Treated with Neoadjuvant Endocrine Therapy

Sella T, Kantor O, Weiss A, Partridge AH, Metzger O, King TA

Cancer Immunology Research

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, Ozgenc I, Noureddine M, Meisenheimer B, Chen M, Piel B, Spicer N, Obua B, Messier CM, Shannon E, Mahadevan NR, Tani T, Schol PJ, Lee-Hassett AM, Zlota A, Vo HV, Ha M, Bertram AA, Han S, Thai TC, Gustafson CE, Venugopal K, Haggerty TJ, Albertson TP, Hartley AV, Eser PO, Li ZH, Vivero M, De Rienzo A, Richards WG, Abu-Yousif AO, Appleman VA, Gregory RC, Parent A, Lineberry N, Smith EL, Jänne PA, Miret JJ, Tolstorukov MY, Romee R, Paweletz CP, Bueno R, Barbie DA

Cancer Immunology Research

Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition

Alvarez-Breckenridge C, Markson SC, Stocking JH, Nayyar N, Lastrapes M, Strickland MR, Kim AE, de Sauvage M, Dahal A, Larson JM, Mora JL, Navia AW, Klein RH, Kuter BM, Gill CM, Bertalan M, Shaw B, Kaplan A, Subramanian M, Jain A, White M, Shahid O, Pauken KE, Miller BC, Frederick DT, Hebert C, Shaw M, Martinez-Lage M, Frosch M, Wang N, Gerstner E, Nahed BV, Curry WT, Carter B, Cahill DP, Boland GM, Sharpe AH, Suva ML, Sullivan RJ, Brastianos PK, Carter SL

Cancer Research

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Nardone A, Qiu X, Nagy Z, Feiglin A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Liu W, Cejas P, Brock JB, Freedman ML, Winer EP, Long HW, Metzger Filho O, Jeselsohn R


Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer

Yamashita N, Fushimi A, Morimoto Y, Bhattacharya A, Hagiwara M, Yamamoto M, Hata T, Shapiro G, Kufe D

Cell Reports Methods

Direct Capture of Neutralized RBD Enables Rapid Point-of-Care Assessment of SARS-CoV-2 Neutralizing Antibody Titer

Jee H, Koehler AN, London WB, Lee PY, Bhatia SN, Li H

Chemical Communications

(15)N-Detected TROSY NMR Experiments to Study Large Disordered Proteins in High-Field Magnets

Dubey A, Viennet T, Chhabra S, Seo HC, Arthanari H

Clinical Cancer Research

Cediranib in Combination with Olaparib in Patients Without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Liu JF

Clinical Cancer Research

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Liu M, Tayob N, Penter L, Sellars M, Tarren A, Chea V, Carulli I, Huang T, Li S, Cheng SC, Le P, Frackiewicz L, Fasse J, Qi C, Liu JF, Stover EH, Curtis J, Livak KJ, Neuberg D, Matulonis UA, Wu CJ, Keskin DB, Konstantinopoulos PA

Clinical Genitourinary Cancer

Impact of Renin-Angiotensin System Inhibitors on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Checkpoint Inhibitors

Nuzzo PV, Adib E, Curran C, Freeman D, Nassar AH, Abou Alaiwi S, Bakouny Z, McGregor BA, Choueiri TK, Jain RK, Sonpavde G

Clinical Lymphoma, Myeloma, and Leukemia

SOHO State of the Art Updates and Next Questions: Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia

Sermer D, Sarosiek S, Branagan AR, Treon SP, Castillo JJ

Computers, Informatics, Nursing

Cancer Survivors' Perspectives of Virtual Yoga for Chronic Chemotherapy-Induced Peripheral Neuropathy Pain During the COVID-19 Pandemic

Knoerl R, Bockhoff J, Fox E, Giobbie-Hurder A, Berfield J, Meyerhardt J, Wright A, Ligibel J

Critical Reviews in Oncology Hematology

Effect of Exercise on Tumor Markers - Is Exercise Anti-Tumorigenic in Humans?: A Scoping Review of Preliminary Clinical Investigations

Kang DW, Vander Heiden MG, Dieli-Conwright CM

Current Opinion in Chemical Biology

Emerging Frontiers in Virtual Drug Discovery: From Quantum Mechanical Methods to Deep Learning Approaches

Gorgulla C, Arthanari H

European Urology

Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73

Carvalho FLF, Mossanen M, Van Allen EM, Mouw KW

European Urology Oncology

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature

Sweeney CJ

Future Oncology

A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an In Situ Vaccine for Cisplatin-Ineligible MIBC: the RAD VACCINE MIBC Trial

Sonpavde GP


A Growing Hope for Earlier Detection of Pancreatic Cancer

Rosenthal M, Schawkat K, Wolpin B

Genome Biology

Differential Richness Inference for 16S rRNA Marker Gene Surveys

Kumar MS, Irizarry RA

Genome Medicine

Whole Genome Sequencing Reveals the Independent Clonal Origin of Multifocal Ileal Neuroendocrine Tumors

Mäkinen N, Zhou M, Zhang Z, Perez E, Nakakura E, Meyerson M

Hematology/Oncology Clinics of North America

Gene Therapy for Pediatric Neurologic Disease

Jimenez-Kurlander L, Duncan CN


Multiple High-Grade and Rare Immune-Related Adverse Events in a Colon Cancer Patient with Genomic and Cytokine Profiling

Tyan K, Abu-Shawer O, Baginska J, Severgnini M, Manos M, Vaitkevicius H, Grover S, Hodi FS, Rahma OE

International Journal of Molecular Sciences 

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression

Yamashita N, Kufe D

Journal of the American Geriatrics Society

Geriatric Surgical Service Interventions in Older Emergency General Surgery Patients: Preliminary Results

Hu FY, O'Mara L, Tulebaev S, Orkaby AR, Cooper Z, Bernacki RE

Journal of Cancer Survivorship

Yoga for Chronic Chemotherapy-Induced Peripheral Neuropathy Pain: A Pilot, Randomized Controlled Trial

Knoerl R, Giobbie-Hurder A, Berfield J, Meyerhardt JA, Wright AA, Ligibel JA

Journal of Clinical Investigation

Degradation of GSPT1 Causes TP53-Independent Cell Death in Leukemia While Sparing Normal Hematopoietic Stem Cells

Sellar RS, Sperling AS, Slabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, Dutta RK, Boettcher S, Lin AE, Sandoval B, Quevedo Barrios VA, Kovalcik V, Koeppel J, Fink EC, Bergstrom EJ, Burt R, Udeshi ND, Carr SA, Fischer ES, Ebert BL

Journal of Clinical Investigation

Satellite Repeat RNA Expression in Epithelial Ovarian Cancer Associates with a Tumor-Immunosuppressive Phenotype

Porter RL, Flores MN, Berzolla E, You E, Phillips IE, Kc N, Desai N, Tai EC, Szabolcs A, Lang ER, Pankaj A, Raabe MJ, Thapar V, Xu KH, Nieman LT, Rabe DC, Kolin DL, Stover EH, Pepin D, Stott SL, Deshpande V, Liu JF, Matulonis UA, Ting DT

Journal of Clinical Sleep Medicine

The Impact of Narcolepsy on Social Relationships in Young Adults

Davidson RD, Biddle K, Nassan M, Scammell TE, Zhou ES

Journal of Genetic Counseling

Patterns of Germline and Somatic Testing After Universal Tumor Screening for Lynch Syndrome: A Clinical Practice Survey of Active Members of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

Rodgers-Fouche L, Perez K

Journal of Investigative Dermatology

Distinct Radiation Responses in Virus-Positive and Virus-Negative Merkel Cell Carcinoma

Ahmed MM, Rivas HG, Frost TC, DeCaprio JA

Journal of the National Comprehensive Cancer Network

Association of Polypharmacy and Potentially Inappropriate Medications with Frailty Among Older Adults with Blood Cancers

Hshieh TT, DuMontier C, Stone RM, Soiffer RJ, Driver JA, Abel GA

Journal of the National Comprehensive Cancer Network

Impact of Genetic Counseling on Patient-Reported Electronic Cancer Family History Collection

Vanderwall RA, Schwartz A, Kipnis L, Skefos CM, Stokes SM, Bhulani N, Weitz M, Gelman R, Garber JE, Rana HQ

Journal of Palliative Medicine

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness

Sager Z, Ljuslin M, Tulsky JA, Beaussant Y

JCI Insight

Patterns of Structural Variation Define Prostate Cancer Across Disease States

Zhou M, Carrot-Zhang J, Beroukhim R, Van Allen EM, Choudhury AD, Freedman M, Taplin ME, Meyerson M, Viswanathan SR

JCO Oncology Practice

Ethics Consultation in Oncology: The Search for Quality in Quantity

Marron JM, Hantel A, Abel GA, Peppercorn JM

JCO Oncology Practice

Sharing Decisions About Systemic Therapy for Advanced Cancers

Tarbi EC, Pirl WF

Leukemia and Lymphoma

Prognostic Value of Minimal Residual Disease Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Joyce RM, Chen YB, Armand P, Merryman RW


Efficacy of Avapritinib Versus Best Available Therapy in the Treatment of Advanced Systemic Mastocytosis

Galinsky IA, DeAngelo DJ

Molecular Cancer Research

Dependence on the MUC1-C Oncoprotein in Classic, Variant and Non-Neuroendocrine Small Cell Lung Cancer

Fushimi A, Moritmoto Y, Ishikawa S, Yamashita N, Bhattacharya A, Daimon T, Rajabi H, Jin C, Hagiwara M, Yasumizu Y, Luan Z, Suo W, Kufe D

Molecular Therapy

Development of a Double ShmiR Lentivirus Effectively Targeting Both BCL11A and ZNF410 for Enhanced Induction of Fetal Hemoglobin to Treat b- Hemoglobinopathies

Liu B, Brendel C, Vinjamur DS, Zhou Y, Harris C, McGuinness M, Manis JP, Bauer DE, Xu H, Williams DA

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies

Bu MT, Yuan L, Klee AN, Freeman GJ

Nature Materials

Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Niches

Vining KH, Marneth AE, Adu-Berchie K, Grolman JM, Tringides CM, Liu Y, Wong WJ, Pozdnyakova O, Severgnini M, Stafford A, Duda GN, Hodi FS, Mullally A, Wucherpfennig KW, Mooney DJ


Liquid Biopsy Detection of Genomic Alterations in Pediatric Brain Tumors from Cell-Free DNA in Peripheral Blood, CSF, and Urine

Pages M, Rotem D, Gydush G, Reed S, Rhoades J, Ha G, Lo C, Fleharty M, Duran M, Jones R, Becker S, Haller M, Sinai CE, Goumnerova L, Golub TR, Ligon KL, Wright KD, Adalsteinsson VA, Beroukhim R, Bandopadhayay P


Trends in Location of Death for Individuals with Primary Brain Tumors in the United States

Aizer AA, Bi WL, Haas-Kogan D, Rahman R


Novel Clinical Trial Designs in Neuro-Oncology

Saraf A, Trippa L, Rahman R

Pain Management Nursing

Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy

Knoerl R, Mazzola E, Hong F, Salehi E, McCleary N, Ligibel J, Reyes K, Berry DL

Pediatric Blood and Cancer

Predictors of Thrombosis in Children Receiving Therapy for Acute Lymphoblastic Leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001

Flamand Y, Blonquist T, Stevenson KE, Harris MH, Neuberg DS, Sallan SE, Silverman LB


Future Directions for Precision Oncology in Prostate Cancer

Mizuno K, Beltran H


PTEN-PI3K Pathway Alterations in Advanced Prostate Cancer and Clinical Implications

Choudhury AD

Radiotherapy and Oncology

Characterization of Clinical Outcomes After Shorter Course Hypofractionated and Standard-Course Radiotherapy for Stage I-III Curatively-Treated Merkel Cell Carcinoma

Liu KX, Milligan MG, Schoenfeld JD, Tishler RB, Ng AK, Devlin PM, Fite E, Hanna GJ, Silk AW, Yoon CH, Thakuria M, Margalit DN

Transplantation and Cellular Therapies

Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

Liu KX, Poux N, Shin KY, Moore N, Chen YH, Margossian S, Whangbo JS, Duncan CN, Lehmann LE, Marcus KJ

Transplantation and Cellular Therapies

Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndromea

Little JS, Shapiro RM, Aleissa MM, Kim A, Chang JBP, Kubiak DW, Zhou G, Antin JH, Koreth J, Nikiforow S, Cutler CS, Romee R, Issa NC, Ho VT, Gooptu M, Soiffer RJ, Baden LR